JP2021531249A5 - - Google Patents

Info

Publication number
JP2021531249A5
JP2021531249A5 JP2020573469A JP2020573469A JP2021531249A5 JP 2021531249 A5 JP2021531249 A5 JP 2021531249A5 JP 2020573469 A JP2020573469 A JP 2020573469A JP 2020573469 A JP2020573469 A JP 2020573469A JP 2021531249 A5 JP2021531249 A5 JP 2021531249A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
formula
pharmaceutical composition
compound according
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020573469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531249A (ja
JP7444797B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/041283 external-priority patent/WO2020014409A1/en
Publication of JP2021531249A publication Critical patent/JP2021531249A/ja
Publication of JP2021531249A5 publication Critical patent/JP2021531249A5/ja
Priority to JP2024025112A priority Critical patent/JP2024059789A/ja
Application granted granted Critical
Publication of JP7444797B2 publication Critical patent/JP7444797B2/ja
Priority to JP2025120296A priority patent/JP2025157418A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020573469A 2018-07-11 2019-07-11 老化細胞除去組成物及びその使用 Active JP7444797B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024025112A JP2024059789A (ja) 2018-07-11 2024-02-22 老化細胞除去組成物及びその使用
JP2025120296A JP2025157418A (ja) 2018-07-11 2025-07-17 老化細胞除去組成物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696486P 2018-07-11 2018-07-11
US62/696,486 2018-07-11
PCT/US2019/041283 WO2020014409A1 (en) 2018-07-11 2019-07-11 Senolytic compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024025112A Division JP2024059789A (ja) 2018-07-11 2024-02-22 老化細胞除去組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2021531249A JP2021531249A (ja) 2021-11-18
JP2021531249A5 true JP2021531249A5 (https=) 2022-07-19
JP7444797B2 JP7444797B2 (ja) 2024-03-06

Family

ID=69140375

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020573469A Active JP7444797B2 (ja) 2018-07-11 2019-07-11 老化細胞除去組成物及びその使用
JP2024025112A Pending JP2024059789A (ja) 2018-07-11 2024-02-22 老化細胞除去組成物及びその使用
JP2025120296A Pending JP2025157418A (ja) 2018-07-11 2025-07-17 老化細胞除去組成物及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024025112A Pending JP2024059789A (ja) 2018-07-11 2024-02-22 老化細胞除去組成物及びその使用
JP2025120296A Pending JP2025157418A (ja) 2018-07-11 2025-07-17 老化細胞除去組成物及びその使用

Country Status (9)

Country Link
US (3) US11026963B2 (https=)
EP (1) EP3790861A4 (https=)
JP (3) JP7444797B2 (https=)
KR (1) KR102843318B1 (https=)
CN (2) CN112469697B (https=)
IL (2) IL312612A (https=)
MX (2) MX2021000395A (https=)
SG (1) SG11202012099VA (https=)
WO (1) WO2020014409A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
AU2021211925A1 (en) 2020-01-20 2022-08-25 Neophore Limited Isoindoline derivatives which bind to an ATP binding site
EP4157460A1 (en) * 2020-06-01 2023-04-05 HCW Biologics, Inc. Methods of treating aging-related disorders
GB202008201D0 (en) * 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
US11857551B1 (en) 2020-07-10 2024-01-02 Ting Therapeutics Llc Methods for the prevention and treatment of hearing loss
WO2023039293A1 (en) * 2021-09-13 2023-03-16 Rubedo Life Sciences, Inc. Coumarin derivatives of sugar analogs and uses thereof
WO2023039292A2 (en) * 2021-09-13 2023-03-16 Rubedo Life Sciences, Inc. Novel sugar derivatives and uses thereof to prepare novel senolytic agents
EP4380575A4 (en) * 2021-09-13 2025-07-23 Rubedo Life Sciences Inc DRUG CONJUGATES OF SUGAR DERIVATIVES AND THEIR USES AS SENOLYTIC AGENTS
CN114249782B (zh) * 2022-01-05 2023-06-30 湖南大学 一种选择性破坏衰老细胞溶酶体的前药及其制备方法与应用
WO2024036961A1 (zh) * 2022-08-19 2024-02-22 北京三秀生物医药科技有限公司 一种抗衰老相关疾病的前药及其使用方法
CN118496288B (zh) * 2023-02-06 2025-01-10 中国科学院微生物研究所 一种糖基化喜树碱类化合物Gly-CPTR及其制药用途、药物或前药及制备方法
EP4687893A1 (en) * 2023-04-06 2026-02-11 Integrated Biosciences, Inc. Compounds and uses thereof
CN116688159A (zh) * 2023-06-19 2023-09-05 江西德上制药股份有限公司 一种基于mRNA技术治疗阿尔茨海默病的药物组合物及制备方法
CN116942653A (zh) * 2023-08-25 2023-10-27 徐诺药业(南京)有限公司 艾贝司他用于制备防治细胞因子风暴相关疾病药物的用途
WO2025175039A1 (en) * 2024-02-13 2025-08-21 Luxvitae Therapeutics Inc. Duocarmycin analogs and applications thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US6664443B1 (en) 1998-05-01 2003-12-16 Mayo Foundation For Medical Education And Research Pathogenic Tau mutations in transgenic mice
NZ517613A (en) 1999-09-08 2004-01-30 Sloan Kettering Inst Cancer Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
CN1257190C (zh) 2003-04-02 2006-05-24 郭全太 聚葡萄糖生产工艺
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
MX2009006542A (es) 2006-12-19 2009-06-30 Methylgene Inc Inhibidores de histona desacetilasa y sus profarmacos.
WO2009042193A1 (en) * 2007-09-25 2009-04-02 Abbott Laboratories Octahydropentalene compounds as chemokine receptor antagonists
WO2009067543A2 (en) * 2007-11-19 2009-05-28 The Regents Of The University Of Colorado Treatment of histone deacetylase mediated disorders
WO2010014814A2 (en) * 2008-07-30 2010-02-04 Wisconsin Alumni Research Foundation Glycosylated warfarin analogs and uses thereof
AU2010222289B2 (en) * 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
US20120005765A1 (en) 2010-07-01 2012-01-05 Saint Louis University Animal model for parkinson's disease
ES2705027T3 (es) 2010-08-19 2019-03-21 Buck Institute For Age Res Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
CN103261200B (zh) * 2010-09-13 2016-03-30 阿迪维纳斯疗法有限公司 作为a2b腺苷受体拮抗剂的前药的嘌呤化合物、它们的制备方法及医药用途
WO2012177927A1 (en) 2011-06-21 2012-12-27 Mayo Foundation For Medical Education And Research Transgenic animals capable of being induced to delete senescent cells
MX2014007093A (es) 2011-12-13 2014-10-13 Buck Inst For Res On Aging Metodos para mejorar terapias medicas.
JP6328098B2 (ja) 2012-03-29 2018-05-23 フィリップス ライティング ホールディング ビー ヴィ 暖房デバイス及び暖房方法
ES2710322T3 (es) 2012-08-28 2019-04-24 Univ Tuebingen Medizinische Fakultaet Trazadores de la senescencia
TW201536324A (zh) 2013-06-19 2015-10-01 Buck Inst For Res On Aging 增加醫藥療法有效性之方法
IL286427B2 (en) * 2014-01-28 2024-08-01 Mayo Found Medical Education & Res Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
EP3139942B1 (en) 2014-05-05 2019-12-18 Bioventures, Llc COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
CA2962922C (en) * 2014-09-29 2021-10-26 The Scripps Research Institute Sphingosine-1-phosphate receptor modulators for treatment of cardiopulmonary disorders
WO2016118859A1 (en) 2015-01-22 2016-07-28 Board Of Trustees Of The University Of Arkansas Compositions and methods for selectively depleting senescent cells comprising flip
WO2016127135A1 (en) * 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditons
CN109152933B (zh) * 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
WO2018146506A1 (en) 2017-02-10 2018-08-16 Universitat Politècnica De València Therapeutic derivatives

Similar Documents

Publication Publication Date Title
JP2021531249A5 (https=)
RU2494095C2 (ru) Модифицированные миметики лизина
EP0600675B1 (en) Indoline compounds for the treatment of dysuria
JP2007519619A5 (https=)
JPS6197256A (ja) アルキルスルホンアミドフエニルアルキルアミン類
WO2008054454A2 (en) Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
JP2005510517A5 (ja) シクロオキシゲナーゼ−２インヒビター／ヒストン・デアセチラーゼ・インヒビター組合せ剤
JP2016539140A (ja) ヒストンデアセチラーゼ阻害剤と免疫調節薬の組合せ
JP2016501241A5 (https=)
RU97103207A (ru) Арилтиосоединения в качестве антибактериальных и противовирусных средств
JPH11503746A (ja) サクシンアミド誘導体と金属タンパク質分解酵素阻害剤としてのその使用
CZ283602B6 (cs) Pyrrolidinové deriváty, způsob jejich přípravy a léčiva tyto deriváty obsahující
CN102781443A (zh) 用于治疗结节病的阿普斯特
EP0793641B1 (en) Metalloproteinase inhibitors
JPH05506643A (ja) Ｎ―フエニル―ｎ―アセトアミドグリシンアミド類、それらの製造およびそれらを含有する薬物
US20080188565A1 (en) Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
DE10006453A1 (de) Piperidylcarbonsäuren als Integrinantagonisten
KR20200075867A (ko) 단백 분해 효소의 쌍두형 저해제
JP2009040767A5 (https=)
JPS6327426A (ja) 胃腸疾患処置剤フェニルエタノ−ルアミン誘導体類
FR2901273A1 (fr) Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
JP3647451B2 (ja) ベンゾラクタム誘導体
RU2013113301A (ru) Замещенные 2-оксо- и 2-тиоксо-дигидрохинолин-3-карбоксамиды в качестве модуляторов kcnq2/3
AP694A (en) Nitro-benzamides useful as anti-arrhythmic agents.
JPH02218654A (ja) 安息香酸誘導体、それらの製造方法およびそれらを含有する薬剤